Paul Revill

Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research

Beth Woods, Paul Revill, Mark Sculpher et al. · Value in Health · 2016 · 925 citations · Full text

Pharmacy, Economics, Pharmacoeconomics +16

The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought

Thomas Wilkinson, Mark Sculpher, Karl Claxton et al. · Value in Health · 2016 · 346 citations

Public Affairs, Economics, Public Policy +12

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models

Jeffrey W. Eaton, Nicolas A. Menzies, John Stover et al. · The Lancet Global Health · 2013 · 246 citations · Full text

Pharmacy, Health Policy, Pharmacoeconomics +17

Sustainable HIV treatment in Africa through viral-load-informed differentiated care

Andrew Phillips, Amir Shroufi, Lara Vojnov et al. · Nature · 2015 · 168 citations · Full text

Public Health, Infectious Diseases, Pharmacoeconomics +17

Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

Andrew Phillips, François Venter, Diane V. Havlir et al. · The Lancet HIV · 2018 · 127 citations · Full text

Public Health, Health Policy, Pharmacology +17